NCT05034484View on ClinicalTrials.gov

A Study of ALPN-303 in Adult Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

February 27, 2023

Study Completion Date

February 27, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

ALPN-303

Multiple dose levels will be evaluated.

DRUG

Placebo

Placebo will be administered

Trial Locations (2)

3004

Investigative Site, Melbourne

4006

Investigative Site, Brisbane

Sponsors
All Listed Sponsors
lead

Alpine Immune Sciences, Inc.

INDUSTRY

NCT05034484 - A Study of ALPN-303 in Adult Healthy Volunteers | Biotech Hunter | Biotech Hunter